Back to Search Start Over

RhoA activation-mediated vascular permeability in capillary malformation-arteriovenous malformation syndrome: a hypothesis.

Authors :
Eisa-Beygi S
Vo NJ
Link BA
Source :
Drug discovery today [Drug Discov Today] 2021 Aug; Vol. 26 (8), pp. 1790-1793. Date of Electronic Publication: 2020 Dec 24.
Publication Year :
2021

Abstract

Capillary malformation-arteriovenous malformation (CM-AVM) syndrome is a class of capillary anomalies that are associated with arteriovenous malformations and arteriovenous fistulas, which carry a risk of hemorrhages. There are no broadly effective pharmacological therapies currently available. Most CM-AVMs are associated with a loss of RASA1, resulting in constitutive activation of RAS signaling. However, protein interaction analysis revealed that RASA1 forms a complex with Rho GTPase-activating protein (RhoGAP), a negative regulator of RhoA signaling. Herein, we propose that loss of RASA1 function results in constitutive activation of RhoA signaling in endothelial cells, resulting in enhanced vascular permeability. Therefore, strategies aimed at curtailing RhoA activity should be tested as an adjunctive therapeutic approach in cell culture studies and animal models of RASA1 deficiency.<br /> (Copyright © 2020 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1878-5832
Volume :
26
Issue :
8
Database :
MEDLINE
Journal :
Drug discovery today
Publication Type :
Academic Journal
Accession number :
33358701
Full Text :
https://doi.org/10.1016/j.drudis.2020.12.012